|
|
|
COLLEGEVILLE, Pa. (AP) - Wyeth and Progenics Pharmaceuticals Inc. said Thursday that early results from a late-stage trial of their drug Relistor did not meet its goal in restoring gastrointestinal function following surgery to the intestine. The study, in a condition known as post-operative...
Full Coverage:
Wyeth and Progenics report preliminary results from clinical trials of Relistor
Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals have reported preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of Relistor. The first of these studies, a Phase II trial, evaluated the effects of an oral...
Wyeth and Progenics report preliminary results from clinical trials of Relistor
Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals have reported preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of Relistor.[...] [ Pharmaceutical Business Review ] -...
Progenics' Mixed Trial Data (at Motley Fool)
By Brian Orelli May 23, 2008 Comments (0) Progenics Pharmaceuticals (Nasdaq: PGNX) and marketing partner Wyeth (NYSE: WYE) released both positive and negative clinical trial data on Thursday. Both of these were for their recently approved opioid-induced constipation (OIC) drug, Relistor. From the...
Wyeth, Progenics, announce preliminary results for Relistor
Singapore, May 23, 2008: Wyeth Pharmaceuticals and Progenics Pharmaceuticals have announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of Relistor (methylnaltrexone bromide). The first of these studies, a phase II trial, evaluated...
UPDATE - Wyeth, Progenics drug misses goal in Phase 3 study (at Reuters)
NEW YORK, May 22 (Reuters) - Wyeth (WYE.N: ) and Progenics Pharmaceuticals Inc (PGNX.O: ) said on Thursday that an intravenous form of their Relistor drug failed to meet its main goal in a late-stage study for addressing gastrointestinal issues following surgery. The Phase 3 study, which also...
Wyeth Pharmaceuticals, Progenics drug has study setback
Wyeth Pharmaceuticals and Progenics Pharmaceuticals said Thursday their experimental drug Relistor, in intravenous form, did not meet primary or secondary end points related to treating bowel dysfunction caused by the use of opioid pain relief medication after abdominal surgery. The companies are...
Progenics, Wyeth drug fails late-stage trial
There's more bad news for Wyeth and Progenics Pharmaceuticals for their late-stage drug Relistor. Researchers say the drug failed to hit a primary endpoint in restoring gastrointestinal function following surgery. Just as in another late-stage trial, preliminary data revealed no significant...
Health Winners & Losers: Progenics (at TheStreet.com)
Health stocks generally rebounded Thursday, as the biotech sector slightly outpaced the broader markets. The Nasdaq and Amex biotechnology indices were up 1.3% and 1%, respectively, while the Amex pharmaceutical index added a less-robust gain of 0.2%. Partners Wyeth WYE...
Progenics' Relistor Fails in POI, but Still Shows Future Promise
Progenics Pharmaceuticals Inc. and partner Wyeth Pharmaceuticals said a Phase III trial of bowel drug Relistor in patients with post-operative ileus (POI) did not meet any of the study's stated goals. But in a bright spot for Tarrytown, N.J.-based Progenics, a Phase II study of oral Relistor, did...
Wyeth, Progenics Drug Misses Goal in Phase 3 Study
Reuters Health - May. 22, 2008 NEW YORK (Reuters) - Wyeth and Progenics Pharmaceuticals Inc said on Thursday that an intravenous form of their Relistor drug failed to meet its main goal in a late-stage study for addressing gastrointestinal issues following surgery. The phase 3 study, which also...
Related categories
Gastrointestinal Symptoms, Constipation, Progenics Pharmaceuticals, GlaxoSmithKline, Adolor
International Editions
English - US | English - UK | Deutsch | Française | Español | Português | Italiano | Česká | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese)Copyright © 2008 Newstin a.s. All rights reserved. 4.2.5,fe-web-4.2.5;commons-4.2.1;api-4.2.1;fe-4.2.3, 10.10.1.29